ONL Therapeutics to Present at the XXVth Biennial Meeting of the International Society for Eye Research
February 13, 2023 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Feb. 13, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
Ocular Implants Market Report will Worth USD 14.73 Billion by 2030 at a CAGR of 5 % : GreyViews
February 09, 2023 08:00 ET
|
GreyViews
Pune India, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Ocular Implants Market Size By Product (Corneal Implants, Glaucoma Implants, Intraocular Lens, Ocular Prosthesis, Orbital Implants, and Others), By...
ONL Therapeutics to Present at 2023 BIO CEO & Investor Conference
February 02, 2023 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Feb. 02, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for ONL1204 Ophthalmic Solution
February 01, 2023 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Feb. 01, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL Therapeutics to Highlight New Data in Upcoming Scientific Presentations at the 46th Annual Macula Society Meeting and the XXVth Biennial Meeting of the International Society for Eye Research
January 26, 2023 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Jan. 26, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL Therapeutics Appoints Sushanta Mallick as Chief Development Officer
February 09, 2022 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Feb. 09, 2022 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
Adverum Mails Letter to Stockholders Highlighting World-Class Board of Directors Overseeing Successful ADVM-022 Commercial Launch
April 21, 2021 08:00 ET
|
Adverum Biotechnologies, Inc.
Sonic’s Nominees Lack Experience and Qualifications to Advance Adverum’s Commercialization Progress or Deliver Global Access to Vision-Saving Gene Therapy Urges Stockholders to Vote the WHITE Proxy...
Adverum Appoints Christopher J. DeRespino as Chief Business Officer
February 18, 2021 16:00 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
ONL Therapeutics Names Connie Chang as Chief Operating Officer
January 19, 2021 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Jan. 19, 2021 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today...
ONL Therapeutics Closes $46.9 Million in Series B Financing to Advance ONL1204 into Three Retinal Disease Indications
December 22, 2020 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Dec. 22, 2020 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today...